Stocks Health care MBIO

NASDAQ · Health care

Mustang Bio, Inc. (MBIO)

It posted a net loss of $3M. At June 30, 2026 it held $15.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

What Mustang Bio, Inc. does

Mustang Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MBIO.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Mustang Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 5, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.16 versus -$0.19.
2. May 5, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.14 versus -$0.05.
3. April 17, 2026
   Stock exchange listing notice 8-K
4. March 19, 2026
   Annual report 10-K · period to December 31, 2025Diluted EPS -$0.39 versus -$38.57.
5. December 23, 2025
   Shareholder vote results 8-K
6. December 3, 2025
   Proxy statement DEF 14A
7. November 7, 2025
   Quarterly report 10-Q · period to September 30, 2025Diluted EPS -$0.07 versus -$1.96.
8. September 5, 2025
   Securities offering prospectus 424B5
9. August 12, 2025
   Passive stake changed SCHEDULE 13G/A
10. August 8, 2025
    Quarterly report 10-Q · period to June 30, 2025Diluted EPS was -$0.19.

Recent insider filings (Forms 3, 4 and 144): 9, the latest on April 27, 2026. Insider transactions on SEC

Insider trades

What the people running Mustang Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns MBIO

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 1,615 shares in total, about $840.4 at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about MBIO

What does Mustang Bio, Inc. do?

Mustang Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MBIO.

Is Mustang Bio, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $3M.

When did Mustang Bio, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026.

Similar companies

Compare MBIO with

Compare MBIO with any company

Follow MBIO

Get an email when Mustang Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow MBIO: get an email when it files

Where the numbers come from

Financial figures are the values Mustang Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.